Haematology 2018

Landmark (from EOI) OS analysis

OS* for non-CMR vs CMR status using Lugano 2014 criteria (N=519)

96.6 (94.4, 97.9)

1.0

0.8

83.8 (72.6, 90.7)

0.6

0.4

Probability

0.2

CMR (n=451) Non-CMR (n=68) Censored

HR 0.22 (95% CI 0.11, 0.45); p<0.0001

0

0

6

12

18

24

30

36

42

48

54

60

Time since end of treatment (months)

No. of patients at risk

CMR Non-CMR

451 68

445 64

438 61

429 58

423 55

346 50

249 36

169 28

76 12

3

Trotman J, et al. ICML 2017

*Patients who died or started a new anti-lymphoma treatment before EOI were excluded